Siemens Healthineers said that it's collaborating with the U.S. Centers for Disease Control and Prevention (CDC) and the Joint Research Centre of the European Commission (EC) on a research project to develop a process for standardizing SARS-CoV-2 assays.
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.
Sherlock Biosciences has formed the 221b Foundation, a nonprofit organization committed to assisting in the eradication of COVID-19, while supporting racial and gender diversity in STEM.
Thermo Fisher Scientific is investing an additional $140 million to further expand its laboratory plastics consumables production to support the global need for COVID-19 testing, development, and manufacturing of therapies and vaccines.
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic. Discuss
Regeneron Pharmaceuticals and the University of Oxford have commenced a phase III clinical trial of potential treatments for COVID-19.
A recent online survey of adults residing in the U.S. found that close to 70% of those surveyed would accept a COVID-19 vaccine if one were widely available. The study findings were published in the journal Vaccine on August 20. Discuss
New images of respiratory tract cultures of the infectious form of SARS-CoV-2 produced in epithelial cells clearly show a vast amount of virus present. The images were captured by Camille Ehre, PhD, assistant professor of pediatrics at the University of North Carolina School of Medicine.
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus and develop associated therapeutics.
Clinical-stage biotechnology company Axon Neuroscience has touted results from a preclinical trial for its COVID-19 vaccine candidate.
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
